Related references
Note: Only part of the references are listed.Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
Haifa Kathrin Al-Ali et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
Jean-Jacques Kiladjian et al.
LANCET HAEMATOLOGY (2020)
Momelotinib for the treatment of myelofibrosis
Li Xu et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
A. Pardanani et al.
LEUKEMIA (2018)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2018)
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Elisa Rumi et al.
BLOOD (2017)
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Vikas Gupta et al.
HAEMATOLOGICA (2017)
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Vikas Gupta et al.
HAEMATOLOGICA (2017)
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Treatment of Myelofibrosis: Old and New Strategies
Alessandra Iurlo et al.
CLINICAL MEDICINE INSIGHTS-BLOOD DISORDERS (2017)
Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Myeloproliferative Neoplasms, Version 2.2017
Ruben Mesa et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A. Pardanani et al.
LEUKEMIA (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular aspects of myeloproliferative neoplasms
Francois Delhhommeau et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment
Omar I. Abdel-Wahab et al.
ANNUAL REVIEW OF MEDICINE (2009)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Myelofibrosis with myeloid metaplasia
G Barosi
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2003)
Share Paper
